Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · IEX Real-Time Price · USD
10.03
-0.19 (-1.86%)
At close: Jul 19, 2024, 4:00 PM
10.17
+0.14 (1.40%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Vir Biotechnology Employees
Vir Biotechnology had 587 employees as of December 31, 2023. The number of employees increased by 11 or 1.91% compared to the previous year.
Employees
587
Change (1Y)
11
Growth (1Y)
1.91%
Revenue / Employee
$135,603
Profits / Employee
-$918,973
Market Cap
1.36B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 587 | 11 | 1.91% |
Dec 31, 2022 | 576 | 132 | 29.73% |
Dec 31, 2021 | 444 | 117 | 35.78% |
Dec 31, 2020 | 327 | 98 | 42.79% |
Dec 31, 2019 | 229 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Phreesia | 1,438 |
Indivior | 1,164 |
BioCryst Pharmaceuticals | 536 |
Dynavax Technologies | 408 |
Nurix Therapeutics | 284 |
Day One Biopharmaceuticals | 155 |
Disc Medicine | 74 |
VIR News
- 3 days ago - Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 - Business Wire
- 26 days ago - Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection - Business Wire
- 6 weeks ago - Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment - Business Wire
- 7 weeks ago - Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer - Business Wire
- 2 months ago - Vir Biotechnology to Host 2024 Annual Meeting of Stockholders - Business Wire
- 2 months ago - Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 - Business Wire
- 2 months ago - Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour' - Business Wire